Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

Phase 3

Active, not recruiting

Conditions: Fabry Disease

Interventions: Drug: Agalsidase alfa
Drug: Venglustat (GZ402671)
Drug: Agalsidase beta (GZ419828)
Drug: Migalastat

First Posted Date: 2022-03-15

Last Posted Date: 2024-12-17

Lead Sponsor: Sanofi

Target Recruit Count: 104

Registration Number: NCT05280548

Locations: 🇺🇸
University of Alabama -The Kirklin Clinic- Site Number : 8400010, Birmingham, Alabama, United States
🇺🇸
University of California Los Angeles Medical Center- Site Number : 8400008, Los Angeles, California, United States
🇺🇸
Emory University School of Medicine - Atlanta- Site Number : 8400009, Atlanta, Georgia, United States

and more 51 locations

Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)

Completed

Conditions: Immune-mediated Thrombocytopenic Purpura

First Posted Date: 2022-03-02

Last Posted Date: 2022-12-14

Lead Sponsor: Sanofi

Target Recruit Count: 4

Registration Number: NCT05263193

Locations: 🇫🇷
Sanofi-Aventis, Chilly-Mazarin, France

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

Phase 3

Recruiting

Conditions: Pruritus

Interventions: Drug: Dupilumab
Drug: Placebo
Drug: Fexofenadine (loratadine if not available)
Drug: Moisturizer

First Posted Date: 2022-03-02

Last Posted Date: 2024-12-10

Lead Sponsor: Sanofi

Target Recruit Count: 208

Registration Number: NCT05263206

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai- Site Number : 8400034, New York, New York, United States
🇯🇵
Investigational Site Number : 3920006, Sapporo, Hokkaido, Japan
🇺🇸
Kern Allergy and Medical Research- Site Number : 8400016, Bakersfield, California, United States

and more 55 locations

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

Phase 2

Terminated

Conditions: Non-squamous Non-small Cell Lung Cancer

Interventions: Drug: Tusamitamab ravtansine

First Posted Date: 2022-02-17

Last Posted Date: 2024-12-13

Lead Sponsor: Sanofi

Target Recruit Count: 22

Registration Number: NCT05245071

Locations: 🇫🇷
Investigational Site Number : 2500001, Creteil, France
🇯🇵
Investigational Site Number : 3920003, Sunto Gun, Shizuoka, Japan
🇯🇵
Investigational Site Number : 3920005, Hirakata-shi, Osaka, Japan

and more 32 locations

Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: SAR443820
Drug: Placebo

First Posted Date: 2022-02-14

Last Posted Date: 2024-04-03

Lead Sponsor: Sanofi

Target Recruit Count: 305

Registration Number: NCT05237284

Locations: 🇺🇸
University of Pennsylvania Site Number : 8400021, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University Hospital Site Number : 8400014, Philadelphia, Pennsylvania, United States
🇨🇦
Investigational Site Number : 1240008, Toronto, Ontario, Canada

and more 60 locations

A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)

Completed

Conditions: Dermatitis Atopic

First Posted Date: 2022-02-11

Last Posted Date: 2023-01-31

Lead Sponsor: Sanofi

Target Recruit Count: 18

Registration Number: NCT05235724

Locations: 🇺🇸
Michigan Dermatology Institute-Site Number:8400059, Waterford, Michigan, United States
🇺🇸
C2 Research Center, LLC-Site Number:8400071, Montgomery, Alabama, United States
🇺🇸
Amedica Research Institute, Inc.-Site Number:8400067, Hialeah, Florida, United States

and more 4 locations

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Phase 1

Terminated

Conditions: Osteogenesis Imperfecta

Interventions: Drug: SAR439459
Drug: Placebo

First Posted Date: 2022-02-09

Last Posted Date: 2024-11-28

Lead Sponsor: Sanofi

Target Recruit Count: 16

Registration Number: NCT05231668

Locations: 🇺🇸
UCLA Health_Site Number: 8400006, Los Angeles, California, United States
🇺🇸
Yale University - Site Number:8400007, New Haven, Connecticut, United States
🇺🇸
Indiana University School of Medicine_Site Number: 8400002, Indianapolis, Indiana, United States

and more 10 locations

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

Phase 3

Active, not recruiting

Conditions: Gaucher's Disease Type III

Interventions: Drug: Venglustat
Drug: imiglucerase

First Posted Date: 2022-02-03

Last Posted Date: 2024-11-04

Lead Sponsor: Sanofi

Target Recruit Count: 43

Registration Number: NCT05222906

Locations: 🇺🇸
Yale University School of Medicine - Investigational Site Number: 8400003, New Haven, Connecticut, United States
🇺🇸
University of Iowa - Investigational Site Number: 8400002, Iowa City, Iowa, United States
🇺🇸
Texas Oncology - Medical City Dallas Site Number : 8400008, Dallas, Texas, United States

and more 19 locations

A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries

Completed

Conditions: Dermatitis Atopic

First Posted Date: 2022-01-28

Last Posted Date: 2023-11-29

Lead Sponsor: Sanofi

Target Recruit Count: 187

Registration Number: NCT05214326

Locations: 🇰🇼
Investigational site Kuwait, Kuwait, Kuwait
🇸🇦
Investigational site Saudi Arabia, Saudi Arabia, Saudi Arabia
🇦🇪
Investigational site United Arab Emirates, United Arab Emirates, United Arab Emirates

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Phase 3

Recruiting

Conditions: Fabry Disease

Interventions: Drug: Venglustat (GZ402671)
Drug: Placebo

First Posted Date: 2022-01-25

Last Posted Date: 2024-11-05

Lead Sponsor: Sanofi

Target Recruit Count: 114

Registration Number: NCT05206773

Locations: 🇺🇸
University of California Irvine Medical Center- Site Number : 8400019, Orange, California, United States
🇺🇸
Emory Genetics- Site Number : 8400010, Atlanta, Georgia, United States
🇺🇸
Westchester Medical Center Healthcare Corporation- Site Number : 8400001, Hawthorne, New York, United States

and more 56 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy